Sydney Lupkin Sydney Lupkin is the pharmaceuticals correspondent for NPR.
Stories By

Sydney Lupkin

Federal Deal To Increase Vaccine Production Could Give Some Employees Early Access

  • Download
  • <iframe src="https://www.npr.org/player/embed/957779150/957779151" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

People line up on Thursday for the first day of Clark County's pilot COVID-19 vaccination program at Cashman Center in Las Vegas. Ethan Miller/Getty Images hide caption

toggle caption
Ethan Miller/Getty Images

COVID-19 Supply Deal Lets Vaccine Maker Earmark Doses For Employees And Their Families

  • Download
  • <iframe src="https://www.npr.org/player/embed/957297895/957813232" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">

U.S. Government To Buy Additional 100 Million Doses Of Pfizer COVID-19 Vaccine

  • Download
  • <iframe src="https://www.npr.org/player/embed/949751699/949751700" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Pfizer, BioNTech Reach Deal To Supply U.S. With More Vaccine Doses

  • Download
  • <iframe src="https://www.npr.org/player/embed/949542443/949547855" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

A worker passes through the security gate at the Moderna campus in Norwood, Mass., one of the sites where the biotechnology company is manufacturing its COVID-19 vaccine. Joseph Prezioso/AFP via Getty Images hide caption

toggle caption
Joseph Prezioso/AFP via Getty Images

How Will Moderna Meet The Demand For Its COVID-19 Vaccine?

  • Download
  • <iframe src="https://www.npr.org/player/embed/947628608/947693915" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

If Pfizer Vaccine Is FDA Approved, What's Trump Administration's Plan For Buying It?

  • Download
  • <iframe src="https://www.npr.org/player/embed/945136585/945136586" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

A vial of the COVID-19 vaccine developed by Pfizer and BioNTech that was used at the Royal Victoria Hospital in Belfast, U.K., on Tuesday. Liam McBurney/Bloomberg via Getty Images hide caption

toggle caption
Liam McBurney/Bloomberg via Getty Images

Novavax released its federal contract to develop and supply a COVID-19 vaccine. The agreement reveals terms that weren't previously known. Bloomberg via Getty Images hide caption

toggle caption
Bloomberg via Getty Images

The Department of Health and Human Services on Saturday made public several contracts with companies working on COVID-19 vaccines as part of Operation Warp Speed. Mark Wilson/Getty Images hide caption

toggle caption
Mark Wilson/Getty Images

Regeneron has developed a drug called REGN-COV2 that is a combination of two monoclonal antibodies that block the virus that causes COVID-19. The company has a contract to supply up to 300 million doses to the U.S. government. Lev Radin/Pacific Press/LightRocket via Getty Images hide caption

toggle caption
Lev Radin/Pacific Press/LightRocket via Getty Images

Moncef Slaoui, a former GlaxoSmithKline executive, speaks during the kickoff announcement for Operation Warp Speed in the White House Rose Garden on May 15. Jabin Botsford/The Washington Post via Getty Images hide caption

toggle caption
Jabin Botsford/The Washington Post via Getty Images

After Months Of Questions, A Key Operation Warp Speed Adviser's Contract Emerges

  • Download
  • <iframe src="https://www.npr.org/player/embed/929284620/929609229" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

A heavily redacted supply contract between the federal government and vaccine developer Moderna, headquartered in Cambridge, Mass., was released Friday. Joseph Prezioso/AFP via Getty Images hide caption

toggle caption
Joseph Prezioso/AFP via Getty Images

FDA Panel To Lay Regulatory Groundwork For COVID-19 Vaccine

  • Download
  • <iframe src="https://www.npr.org/player/embed/926537946/926537947" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript